Advertisement

CRL

Charles River Laboratories International, Inc.

Healthcare · USD

Set alert

Price alert · CRL

All alert types
359.41 USD -16.69 -4.44%
As of Oct 30, 2026 Extended hours 365.29 +1.64%
Bid
359.26 × 300
Ask
359.75 × 200
351.98 Day range 374.40
149.93 52-week range 376.10
YTD
+80.17%
1 year
+100.66%
Open
372.99
Prev close
376.10
Mkt cap
17.16B
Vol
1.50M
Avg vol
1.02M
EPS
-4.80
P/E
0.00
Div yield
0.00%
More statistics
Low
351.98
High
374.40
Forward P/E
28.20
Beta
1.40
Short ratio
2.77
Inst. own
122.19%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
300.55
200-d avg
221.07
1y target
318.87

5D chart

Chart tools
Interval
CRL five-day price chart345.9354.3362.8371.2379.6Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
17.16B
Enterprise value
20.85B
Trailing P/E
0.00
Forward P/E
28.20
PEG ratio
0.12
Price / sales
4.29
Price / book
6.04
EPS (TTM)
-4.80
Beta
1.40
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-5.96%
Revenue (TTM)
4.00B
Revenue growth
-2.70%
Free cash flow
468.86M
Total cash
192.02M
Total debt
3.03B
Return on equity
-7.52%
Shares outstanding
47.74M
Short % of float
6.86%
50-day average
300.55
200-day average
221.07

Analyst view

Consensus: buy

Buy
Price target (mean) 318.87 -11.3% downside
Target (low)
145.00
Target (mean)
318.87
Target (high)
390.00
Ratings (0m) 17 14 buy · 2 hold · 1 sell
  • Strong buy3
  • Buy11
  • Hold2
  • Sell1
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 2.97.

Earnings history

Financials — quick view

All financials
CRL Revenue — quarterly 1.00B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CRL Net income — quarterly -1.48M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CRL EPS — quarterly -0.03
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CRL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 27, 20262.97———
Aug 5, 2026Jun 27, 20262.743.02+0.28+10.22%
May 7, 2026Mar 28, 20261.962.06+0.10+5.10%
Feb 18, 2026Dec 27, 20252.332.39+0.06+2.58%
Nov 5, 2025Sep 27, 20252.322.43+0.11+4.74%
Aug 6, 2025Jun 28, 20252.503.12+0.62+24.80%

Upgrades / downgrades

CRL analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026Morgan StanleymainOverweightOverweight
Sep 28, 2026JefferiesmainBuyBuy
Sep 25, 2026Deutsche BankmainBuyBuy
Sep 25, 2026TD CowenmainBuyBuy
Sep 25, 2026Evercore ISI GroupmainOutperformOutperform
Sep 25, 2026RBC CapitalmainOutperformOutperform

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
criver.com

News

Your note

Sign in to keep a note on CRL — it syncs with the Stock Master app.

Insider holders

CRL insider holders
InsiderRelationLatest transactionDateShares held
BARBO WILLIAM DOfficerStock GiftNov 6, 20240
COLEMAN GLENN GChief Financial OfficerStock Award(Grant)May 28, 202627,752
CREAMER VICTORIA LOfficerSaleAug 5, 202630,051
FOSTER JAMES CDirectorSaleOct 21, 2026233,410
GIRSHICK BIRGITChief Executive OfficerStock GiftAug 18, 202679,288
LAPLUME JOSEPH WOfficerStock GiftAug 9, 202631,041

Institution ownership

CRL institution ownership
Holder% heldSharesValueReported
FMR, LLC8.88%4,239,7521.52BJun 29, 2026
Blackrock Inc.7.96%3,798,5601.37BJun 29, 2026
Vanguard Capital Management LLC6.60%3,149,2881.13BJun 29, 2026
Invesco Ltd.6.25%2,984,7851.07BJun 29, 2026
Harris Associates L.P.4.69%2,241,144805.58MJun 29, 2026
Vanguard Portfolio Management LLC4.63%2,210,979794.74MJun 29, 2026

Fund ownership

CRL fund ownership
Holder% heldSharesValueReported
Fidelity Contrafund3.82%1,825,159656.05MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.21%1,530,171550.02MJun 29, 2026
HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund3.14%1,498,000538.46MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%1,247,732448.50MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.31%1,104,850397.14MJun 29, 2026
ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund1.64%784,906282.13MAug 30, 2026
Advertisement